204 related articles for article (PubMed ID: 38535033)
21. [Advances in Predictive Research of Immune Checkpoint Inhibitors-related
Adverse Events].
Zhang J; Chen X; Ma S
Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):789-794. PubMed ID: 37989342
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report.
Imakita T; Fujita K; Kanai O; Mio T
Case Rep Oncol; 2022; 15(2):732-737. PubMed ID: 36157702
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
24. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
Johkoh T; Lee KS; Nishino M; Travis WD; Ryu JH; Lee HY; Ryerson CJ; Franquet T; Bankier AA; Brown KK; Goo JM; Kauczor HU; Lynch DA; Nicholson AG; Richeldi L; Schaefer-Prokop CM; Verschakelen J; Raoof S; Rubin GD; Powell C; Inoue Y; Hatabu H
Chest; 2021 Mar; 159(3):1107-1125. PubMed ID: 33450293
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
26. Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade.
Galant-Swafford J; Troesch A; Tran L; Weaver A; Doherty TA; Patel SP
Oncology; 2020; 98(2):123-130. PubMed ID: 31665718
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
[No Abstract] [Full Text] [Related]
28. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
29. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
Ichimura T; Hinata M; Ichikura D; Suzuki S
Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
[TBL] [Abstract][Full Text] [Related]
30. The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports.
Mojsak D; Dębczyński M; Kuklińska B; Moniuszko-Malinowska A; Mróz RM
Am J Case Rep; 2022 Jun; 23():e936420. PubMed ID: 35648729
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review.
Jayakrishnan B; Al-Moundhri M; Burney I; Al-Hashami Z; Al-Bimani K
Adv Respir Med; 2022; 90(3):219-229. PubMed ID: 35731114
[TBL] [Abstract][Full Text] [Related]
34. Iatrogenic pulmonary lesions.
Roden AC; Camus P
Semin Diagn Pathol; 2018 Jul; 35(4):260-271. PubMed ID: 29631763
[TBL] [Abstract][Full Text] [Related]
35. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
[TBL] [Abstract][Full Text] [Related]
36. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary adverse events following immune checkpoint inhibitors.
Spagnolo P; Chaudhuri N; Bernardinello N; Karampitsakos T; Sampsonas F; Tzouvelekis A
Curr Opin Pulm Med; 2022 Sep; 28(5):391-398. PubMed ID: 35838354
[TBL] [Abstract][Full Text] [Related]
38. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
39. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
[TBL] [Abstract][Full Text] [Related]
40. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
